|

Detection of Minimal Residual Disease Using Exosomal miRNA Distant Metastasis Markers

RECRUITINGSponsored by City of Hope Medical Center
Actively Recruiting
SponsorCity of Hope Medical Center
Started2025-01-15
Est. completion2026-06-18
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07243015

Summary

Gastric cancer (GC) is a leading cause of cancer-related death worldwide. Even in patients undergoing curative surgery for non-metastatic disease, postoperative recurrence frequently occurs due to undetected minimal residual disease (MRD). This study aims to establish a highly sensitive and specific liquid biopsy assay using exosomal microRNAs (exo-miRNAs) to detect MRD and predict distant metastasis before clinical recurrence.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Histologically confirmed gastric adenocarcinoma.
* Underwent curative-intent resection (R0).
* Availability of pre- and postoperative plasma samples.
* Documented clinical follow-up data (recurrence/metastasis status).
* Provided written informed consent.

Exclusion Criteria:

* Insufficient plasma volume or RNA quality for exosomal extraction.
* Presence of synchronous or metachronous malignancies.
* Received neoadjuvant chemotherapy without postoperative follow-up.
* Lack of consent or incomplete clinicopathologic data.

Conditions2

CancerGastric Cancer

Locations1 site

City of Hope Medical Center
Duarte, California, 91016
Ajay Goel, PhD626-218-3452ajgoel@coh.org

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.